BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study

BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study::Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation...